<?xml version="1.0" encoding="UTF-8"?>
<document id="29802988">
	<sentence id="s1" text="Recent studies in RAS wild-type (WT) metastatic colorectal cancer (mCRC) suggest that the survival benefits of therapy using anti-epidermal growth factor receptor (anti-EGFR) and anti-vascular endothelial growth factor (anti-VEGF) antibodies combined with chemotherapy are maximized when the anti-EGFR antibody is given as first-line, followed by subsequent anti-VEGF antibody therapy.">
		<entity id="s1.e1" charOffset="59-65"
			type="HP" text="cancer" ontology_id="HP_0002664"/>
		<entity id="s1.e2" charOffset="169-173"
			type="GENE" text="EGFR" ontology_id="1956"/>
		<entity id="s1.e3" charOffset="225-229"
			type="GENE" text="VEGF" ontology_id="7422"/>
		<pair id="s1.p1" e1="s1.e1"
		    e2="s1.e2" pgr="true"/>
		<pair id="s1.p2" e1="s1.e1"
		    e2="s1.e3" pgr="false"/>
	</sentence>
</document>
